Last $35.49 USD
Change Today -0.405 / -1.13%
Volume 144.3K
HAE On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 3:03 PM 07/24/14 All times are local (Market data is delayed by at least 15 minutes).

haemonetics corp/mass (HAE) Snapshot

Open
$35.90
Previous Close
$35.89
Day High
$36.05
Day Low
$35.41
52 Week High
07/25/13 - $45.90
52 Week Low
05/1/14 - $29.86
Market Cap
1.8B
Average Volume 10 Days
200.2K
EPS TTM
$1.72
Shares Outstanding
51.5M
EX-Date
--
P/E TM
20.7x
Dividend
--
Dividend Yield
--
Current Stock Chart for HAEMONETICS CORP/MASS (HAE)

Related News

No related news articles were found.

haemonetics corp/mass (HAE) Related Businessweek News

No Related Businessweek News Found

haemonetics corp/mass (HAE) Details

Haemonetics Corporation is engaged in the design, development, manufacture, and marketing of automated blood component collection devices and surgical blood salvage devices in the United States and internationally. It provides various plasma products, including PCS brand plasma collection equipment and consumables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and blood center products comprising multicomponent collection system brand apheresis equipment to collect specific blood components integrated from the donor, automated cell processor brand solution to automate the washing and freezing of red cell components in the lab, and filtration products. The company also offers various hospital products, such as TEG thrombelastograph hemostasis analyzer system that measures a patient's hemostasis or the ability to form and maintain blood clots; Cell Saver system for cardiovascular surgery procedures; OrthoPAT surgical blood salvage system for orthopedic procedures; and IMPACT Online Web-based software platform that monitors and measures improvements in a hospital’s blood management practices. In addition, it offers SafeTrace Tx and BloodTrack suite of solutions, as well as El Dorado Donor donation and blood unit management systems. The company markets and sells its products to bio-pharmaceutical companies, blood collection groups and independent blood centers, hospitals and hospital service providers, group purchasing organizations, and national health organizations through its direct sales force, as well as independent distributors. Haemonetics Corporation was founded in 1971 and is headquartered in Braintree, Massachusetts.

3,782 Employees
Last Reported Date: 05/22/14
Founded in 1971

haemonetics corp/mass (HAE) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $600.0K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $718.0K
President of Global Plasma
Total Annual Compensation: $588.9K
Executive Vice President of Global Manufactur...
Total Annual Compensation: $455.0K
Chief Science & Technology Officer
Total Annual Compensation: $441.0K
Compensation as of Fiscal Year 2014.

haemonetics corp/mass (HAE) Key Developments

Charles J. Dockendorff Joins Haemonetics Corporation Board of Directors

Haemonetics Corporation announced that Charles J. Dockendorff was elected to the Board of Directors at the company's annual meeting of stockholders on July 23, 2014. Mr. Dockendorff, is Executive Vice President and Chief Financial Officer with Covidien PLC. Before joining Covidien and its predecessors, Mr. Dockendorff was CFO, Vice President of Finance and Treasurer of Epsco Inc. and the CFO of Infrared Industries Inc.

Haemonetics Corporation, Annual General Meeting, Jul 23, 2014

Haemonetics Corporation, Annual General Meeting, Jul 23, 2014., at 08:00 US Eastern Standard Time. Location: the Boston Quincy Marriott, 1000 Marriott Drive. Agenda: To elect three directors as more fully described in the accompanying Proxy Statement; to approve amendments to the company’s 2005 Long-Term Incentive Compensation Plan to increase the number of shares issuable under the Plan by 4,800,000 shares, extend the term of the Plan, and alter the rate at which certain awards are counted toward Plan limits; to consider and act upon an advisory vote regarding the compensation of named executive officers; to ratify Ernst & Young LLP as independent registered public accounting firm to audit the consolidated financial statements of the company and its subsidiaries for the fiscal year ended March 28, 2015; and to consider and act upon any other business which may properly come before the meeting.

Haemonetics Corporation Presents at William Blair & Company's 34th Annual Growth Stock Conference, Jun-11-2014 01:20 PM

Haemonetics Corporation Presents at William Blair & Company's 34th Annual Growth Stock Conference, Jun-11-2014 01:20 PM. Venue: Four Seasons Hotel, 120 East Delaware Place, Chicago, Illinois, United States. Speakers: Christopher J. Lindop, Chief Financial Officer, Executive Vice President of Business Development and Member of Operating Committee.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HAE:US $35.49 USD -0.40

HAE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cerner Corp $55.70 USD -0.27
Fresenius SE & Co KGaA €109.35 EUR -0.31
McKesson Corp $193.03 USD +2.35
Medtronic Inc $63.33 USD -0.04
View Industry Companies
 

Industry Analysis

HAE

Industry Average

Valuation HAE Industry Range
Price/Earnings 53.5x
Price/Sales 2.0x
Price/Book 2.2x
Price/Cash Flow 52.6x
TEV/Sales 1.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HAEMONETICS CORP/MASS, please visit www.haemonetics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.